Hepatopulmonary syndrome (HPS) is a lung complication in various liver diseases, with high incidence, poor prognosis and no effective non-surgical treatments in patients with hepatocirrhosis. Therefore, assessing HPS pathogenesis to explore proper therapy strategies is clinically relevant. In the present study, male Sprague–Dawley rats underwent sham operation or common bile duct ligation (CBDL). Two weeks post-surgery, the following groups were set up for 2 weeks of treatment: sham + normal saline, CBDL + CXCR2 antagonist SB225002, CBDL + tumour necrosis factor α (TNF-α) antagonist PTX and CBDL + normal saline groups. Liver and lung tissues were collected after mean arterial pressure (MAP) and portal venous pressure (PVP) measurements. Haematoxylin and eosin (H&E) staining (lung) and Masson staining (liver) were performed for pathological analyses. Finally, pulmonary tissue RNA and total protein were assessed for target effectors. The mRNA and protein levels of CXCR2 were significantly increased in the pulmonary tissue of CBDL rats. What's more, CXCR2 inhibition by SB225002 reduced the expression of CD68 and von Willebrand factor (vWf) in CBDL rats. Importantly, CXCR2 inhibition suppressed the activation of Akt and extracellular signal-regulated kinase (ERK) in CBDL rats. Antagonization of TNF-α with PTX down-regulated the expression of CXCR2. During HPS pathogenesis in rats, CXCR2 might be involved in the accumulation of pulmonary intravascular macrophages and angiogenesis, possibly by activating Akt and ERK, with additional regulation by TNF-α that enhanced pulmonary angiogenesis by directly acting on the pulmonary tissue. Finally, the present study may provide novel targets for the treatment of HPS.
Skip Nav Destination
Article navigation
January 2017
-
Cover Image
Cover Image
Masson staining of rat liver specimens. Please see pp. 159-168 for more information. Image provided by Xujiong Li.
Research Article|
December 23 2016
CXCR2 is involved in pulmonary intravascular macrophage accumulation and angiogenesis in a rat model of hepatopulmonary syndrome
Xujiong Li;
*Department of Physiology, Changzhi Medical College, Changzhi 046000, China
Correspondence: Xujiong Li (email [email protected])
Search for other works by this author on:
Yunxia Chen;
Yunxia Chen
†Department of Microbiology, Changzhi Medical College, Changzhi 046000, China
Search for other works by this author on:
Yongli Chang;
Yongli Chang
*Department of Physiology, Changzhi Medical College, Changzhi 046000, China
Search for other works by this author on:
Shufen Li;
Shufen Li
*Department of Physiology, Changzhi Medical College, Changzhi 046000, China
Search for other works by this author on:
Zhongfu Zhao;
Zhongfu Zhao
‡Institute of Liver Disease, Changzhi Medical College, Changzhi 046000, China
Search for other works by this author on:
Huiying Zhang
Huiying Zhang
§Department of Pathophysiology, Changzhi Medical College, Changzhi 046000, China
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
August 03 2016
Revision Received:
November 03 2016
Accepted:
November 22 2016
Accepted Manuscript online:
November 22 2016
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society
2016
Clin Sci (Lond) (2017) 131 (2): 159–168.
Article history
Received:
August 03 2016
Revision Received:
November 03 2016
Accepted:
November 22 2016
Accepted Manuscript online:
November 22 2016
Citation
Xujiong Li, Yunxia Chen, Yongli Chang, Shufen Li, Zhongfu Zhao, Huiying Zhang; CXCR2 is involved in pulmonary intravascular macrophage accumulation and angiogenesis in a rat model of hepatopulmonary syndrome. Clin Sci (Lond) 1 January 2017; 131 (2): 159–168. doi: https://doi.org/10.1042/CS20160593
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |